Pharmaceutical Extrusion Applications: Desktop HME for Drug Development
Hot melt extrusion is an established pharmaceutical processing technique. Desktop extrusion equipment now brings this capability within reach of early-stage pharmaceutical R&D programmes.
HME in Drug Development
Hot melt extrusion has been used in pharmaceutical manufacturing for decades, primarily for producing solid dispersions — formulations in which an active pharmaceutical ingredient (API) is molecularly dispersed within a polymer carrier. The principal benefit is bioavailability enhancement: poorly soluble APIs convert to an amorphous solid dispersion that dissolves more rapidly and completely than the crystalline form.
Desktop HME for Early-Stage Research
The development pathway for a pharmaceutical HME formulation begins with screening — identifying appropriate carrier polymers, plasticisers, and process conditions for a specific API. This phase requires the ability to produce small quantities of material rapidly, change formulation variables systematically, and characterise the output. Industrial HME equipment is poorly suited to this phase; the minimum batch sizes and cleaning requirements make rapid iteration impractical and expensive.
Desktop extrusion equipment bridges this gap. Batch sizes of 50–200g are practical, material changeover is achievable within an hour, and the real-time monitoring available on precision equipment provides direct insight into melt behaviour invaluable for formulation screening.
Equipment Requirements for Pharmaceutical HME
Pharmaceutical applications place specific demands on extrusion equipment. Temperature precision is critical — many APIs have narrow thermal stability windows. Contact surfaces should be stainless steel with appropriate surface finish. Documentation of processing conditions per batch is required for traceability. The Noztek Nexus platform meets these requirements with multi-zone temperature control, real-time process monitoring, and full process data logging.